COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary (GreKo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01584297
Recruitment Status : Terminated (Insufficient recruitment rate)
First Posted : April 24, 2012
Last Update Posted : January 21, 2015
Information provided by (Responsible Party):
Grupo Español de Tumores Huérfanos e Infrecuentes

Brief Summary:

Our proposal is to conduct an open phase II clinical trial that allows us to explore the activity of ketoconazole, an inhibitor of the enzyme CYP17, in ovarian granulosa tumors similar to what has been done in prostate cancer. The rational is based on dysregulation that FOXL2 mutations present in almost all granulosa tumors result in the expression of CYP17 that appears to be key in the development and progression of the disease.

This work would represent the first attempt to address the treatment of ovarian granulosa cancer with a molecular solid rational, drawing on the recent identification of the mutation "leader" of this tumor. If succeed provide a widely available therapeutic alternative compared with current cancer therapies, with low toxicity. In addition it would open a new line of research with CYP17 enzyme inhibitors that could alter the course and outcome, usually fatal, in advanced stages of disease.

Condition or disease Intervention/treatment Phase
Granulosa Cell Tumour of the Ovary Drug: Ketoconazole Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.
Study Start Date : October 2012
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Arm Intervention/treatment
Experimental: Ketoconazole
Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
Drug: Ketoconazole
Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
Other Name: Fungarest

Primary Outcome Measures :
  1. Overall response rate [ Time Frame: Every 8 weeks ]
    The primary endpoint is overall response rate, defined as the proportion of patients with response defined as complete or partial response according to RECIST CRITERIA 1.1 measured by an external evaluator

Secondary Outcome Measures :
  1. Clinical benefit [ Time Frame: Every 8 weeks ]
    Clinical benefit defined as stable disease for more than 6 months plus complete and partial response rates, measured by an external evaluator.

  2. Progression-free survival [ Time Frame: Every 8 weeks ]
    Progression-free survival is defined as the time since the start of treatment until progressive disease assessed (through evaluation by an external radiologist) according to RECIST 1.1, or death by any cause.

  3. Overall survival [ Time Frame: Untill death ]
    Overall survival, defined as the time since the start of treatment until the patient dies by any cause.

  4. Quality of life [ Time Frame: Every 4 weeks ]
    Quality of life measured by the validated in Spanish EORTC QLQ-C30 questionnaire.

  5. Safety profile [ Time Frame: Every 4 weeks ]
    Toxicities will be classified according to the NCI-CTCAE v4.03

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients obtained their written informed consent.
  • Women ≥18 years old.
  • ECOG ≤ 1.
  • Histologically confirmed carcinoma of granulosa cell in ovary.
  • Availability of sufficient biopsy material to confirm the diagnosis by a centralized pathologist and determination of the FOXL2 402C mutation → G (C134W).
  • Metastatic or unresectable disease.
  • Imaging measurable disease.
  • Life expectancy ≥ 12 weeks.
  • Patients with adequate hepatic function, defined by:
  • Serum values of AST and ALT ≤ 3 x UNL (except in the presence of metastases then allowed values ≤ 5 x UNL)
  • Total bilirubin ≤ 1.5 x UNL
  • Patients with adequate bone marrow function, defined by:
  • Absolute neutrophil count ≥ 1.5 x 10*9 / L
  • Platelets ≥ 100 x 10*9 / L
  • Hb > 9 g / dL
  • Patients with adequate renal function: serum creatinine ≤ 1.5 x UNL.
  • Absence of any impediment to comply with the study protocol.
  • Women of childbearing potential, sexually active, not under hysterectomy or bilateral adnexectomy, should follow the following guidelines on contraception:
  • Negative serum or urine pregnancy test within 72 hours before the start of treatment.
  • Use of a medically accepted contraceptive method during: the 2 months prior to study treatment, during the study and 3 months after the last dose of study treatment.

Exclusion Criteria:

  • Patients with another primary tumor 2 years before starting the study drug, with the exception of cervical carcinoma in situ or adequately treated or removed completely or basalioma or superficial bladder carcinoma.
  • Patients received radical radiotherapy ≤ 4 weeks before starting the study treatment or who have not recovered from the toxicities of radiotherapy. Palliative radiotherapy of painful bone lesions is allowed up to 14 days before the start of study treatment.
  • Patients with heart failure or clinically significant heart disease, including any of the following:
  • History or presence of uncontrolled severe ventricular arrhythmia.
  • Clinically significant bradycardia at rest.
  • LVEF <45% assessed by 2-D echocardiogram (ECHO) or MUGA.
  • Any of the following diseases within 6 months prior to the start of study drug: Myocardial infarction (MI), severe or unstable angina, coronary revascularization, congestive heart failure (CHF), stroke (CVA), transient ischemic attack (TIA).
  • Patients with gastrointestinal function failure or gastric disease that significantly alter the ketoconazole absorption, for example, severe ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption, extensive resection (> 1m) of the small intestine or inability to swallow oral medication. The partial or total gastrectomy is not an exclusion criteria.
  • Diagnosis of infection with human immunodeficiency virus (HIV).
  • Pregnant women or nursing.
  • Women of childbearing potential not using effective contraceptive method.
  • Patients who are unwilling or unable to comply with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01584297

Layout table for location information
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain, 15706
Hospital Central de Asturias
Oviedo, Asturias, Spain, 33006
Hospital Universitario Fundación Alcorcón
Alcorcón, Madrid, Spain, 28922
Hospital del Mar
Barcelona, Spain, 08003
Hospital Reina Sofía
Cordoba, Spain, 14004
Hospital La Paz
Madrid, Spain, 28046
Hospital Morales Meseguer
Murcia, Spain, 30008
Complejo Hospitalario de Navarra
Navarra, Spain, 31008
Hospital Son Llatzer
Palma de Mallorca, Spain, 07198
Hospital Universitario y Politécnico La Fe
Valencia, Spain, 46026
Sponsors and Collaborators
Grupo Español de Tumores Huérfanos e Infrecuentes
Layout table for investigator information
Study Director: Jesus Garcia-Donas, MD Hospital Universitario Fundación de Alcorcón, Servicio de Oncología Médica, c/ Budapest, 1,28922 Alcorcón (Madrid), Spain
Layout table for additonal information
Responsible Party: Grupo Español de Tumores Huérfanos e Infrecuentes Identifier: NCT01584297    
Other Study ID Numbers: GETHI 2011-03
2012-001948-21 ( EudraCT Number )
First Posted: April 24, 2012    Key Record Dates
Last Update Posted: January 21, 2015
Last Verified: January 2015
Keywords provided by Grupo Español de Tumores Huérfanos e Infrecuentes:
Granulosa Cell Tumour
Additional relevant MeSH terms:
Layout table for MeSH terms
Granulosa Cell Tumor
Sex Cord-Gonadal Stromal Tumors
Neoplasms, Gonadal Tissue
Neoplasms by Histologic Type
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors